Printer Friendly

RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)

 COLLEGEVILLE, Pa., and ROCHESTER, N.Y., Dec. 31 /PRNewswire/ -- Rhone-Poulenc Rorer Pharmaceuticals Inc. (NYSE: RPR) and Fisons Pharmaceuticals announced today an agreement in principle to co-promote two complementary anti-inflammatory drugs for the treatment of asthma.
 A combined sales force of 800 representatives will market Rhone- Poulenc Rorer's Azmacort(R) (triamcinolone acetonide), the leading metered dose inhaled steroid in the United States and Fison's Tilade(R), a new class of anti-inflammatory drug approved for marketing by the Food and Drug Administration on Dec. 30, 1992.
 "Co-promotion will enable us to focus on the need to treat asthma as an inflammatory disease with virtually every physician in the United States that treats this condition," said Randy Thurman, president of Rhone-Poulenc Rorer Pharmaceuticals Inc.
 Glenn Mattes, vice president and division manager of the Rorer Division of RPR Pharmaceuticals, Inc. added, "Both the National Heart, Lung and Blood Institute (NHBLI) of the National Institutes of Health and the International Consensus Report on Asthma have recently urged first-line anti-inflammatory treatment of asthma."
 Asthma is a respiratory condition characterized by symptoms caused by airway obstruction, such as coughing, chest tightness, wheezing and shortness of breath. The condition affects more than 10 million Americans and is one of the leading causes of school and work absences. Although problems are often separated by symptom-free periods, asthma is a chronic disease.
 Heimo Reulecke, president of Fisons, stated, "Our representatives will also increase physician awareness of the benefit of anti- inflammatory drugs as suitable adjunctive therapy for those patients with chronic asthma who are not controlled by beta-2 agonists."
 Tilade is a non-steroid, inhaled, anti-inflammatory agent for asthma. It has been proven safe and effective as a bronchial anti- inflammatory agent in treating mild to moderate asthma in patients, age 12 and older, and contributes significantly to the better management of asthma for this major patient group. Daily dosing provides patient benefits by reducing both symptoms and bronchial hyperreactivity in asthmatic patients.
 Azmacort is indicated for patients who require chronic treatment with corticosteroids for the control of the symptoms of bronchial asthma. Patients administer the metered-dose aerosol via a unique, built-in spacer device.
 Mattes concluded, "We are confident that we will continue to grow Azmacort's market share lead in the inhaled steroid market. Our combined efforts will also result in a successful launch of Tilade."
 Fisons PLC is a UK-based international company headquartered in Ipswich, Suffolk. Reporting sales of more than $2 billion in 1991, the company employs 14,500 people worldwide and operates in more than 100 countries.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, marketing and manufacturing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and has invested more than $500 million in research and development in 1992.
 /delval/
 -0- 12/31/92
 /CONTACT: Ellen Kovak or Eileen Masciale of Fisons Pharmaceuticals, 212-246-0540, or Bob Pearson of Rhone-Poulenc Rorer, 215-454-3872/
 (RPR)


CO: Rhone-Poulenc Rorer Pharmaceuticals Inc.; Fisons Pharmaceuticals ST: Pennsylvania, New York IN: MTC SU: JVN

CC-JS -- PH013 -- 0904 12/31/92 12:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 31, 1992
Words:507
Previous Article:PRIME BANCORP, INC. COMPLETES PURCHASE
Next Article:JOHN W. SNOW RESIGNS FROM COLUMBIA GAS SYSTEM BOARD OF DIRECTORS
Topics:


Related Articles
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
COMPUMED AND RHONE-POULENC RORER SIGN AGREEMENT TO PROMOTE BONE MINERAL DENSITY TESTS
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RPR AND 3M ANNOUNCE MAXAIR(TM) AUTOHALER(TM) (PIRBUTEROL ACETATE INHALATION AEROSOL) CO-PROMOTION AGREEMENT
RHONE-POULENC RORER AND FISONS SIGN AGREEMENTS TO MARKET RESPIRATORY PRODUCTS IN EUROPE
Rhone-Poulenc Rorer and AMRAD Announce Collaboration To Discover New Asthma/Allergy Medicines
Rhone-Poulenc Rorer Inc. to Evaluate NanoSystems Drug Delivery Technology For Asthma

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters